RMTGOTCRetail-Retail Stores, NECFiscal year ends December 31
Regenerative Medical Technology Group Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$0.04−0.00 (-5.76%)
Close on Oct 19, 2026
- Market cap
- $497.25K
- P/E (TTM)
- –
- Dividend yield
- –
Regenerative Medical Technology statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Retail-Retail Stores, NEC companies for comparison
Valuation
| Measure | Regenerative Medical Technology | Industry median |
|---|---|---|
| Market Cap | $516.59K | $99.16M |
| Enterprise Value | -$38.06M | $119.46M |
| PS Ratio | 0.05 | 0.56 |
| P/OCF Ratio | 1.92 | 9.43 |
Enterprise value
| Measure | Regenerative Medical Technology | Industry median |
|---|---|---|
| EV / Sales | -4.04 | 0.60 |
| EV / EBITDA | -93.60 | 10.75 |
| EV / EBIT | -870.49 | 11.21 |
Income (trailing twelve months)
| Measure | Regenerative Medical Technology | Industry median |
|---|---|---|
| Revenue | $9.41M | $366.90M |
| Gross Profit | $5.63M | $250.49M |
| Operating Income | $43.73K | -$275.87K |
| Net Income | -$9.53M | -$948.56K |
| EBITDA | $406.65K | $185.52K |
| EPS (Diluted) | -$0.75 | $0.00 |
Margins
| Measure | Regenerative Medical Technology | Industry median |
|---|---|---|
| Gross Margin | 59.8% | 39.8% |
| Operating Margin | 0.46% | -0.44% |
| Profit Margin | -101.2% | -0.34% |
| EBITDA Margin | 4.32% | 1.22% |
| FCF Margin | -6.19% | 1.51% |
Returns
| Measure | Regenerative Medical Technology | Industry median |
|---|---|---|
| Return on Assets (ROA) | -184.4% | -2.25% |
Growth
| Measure | Regenerative Medical Technology | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 94.3% | 5.86% |
| Revenue Growth (3Y CAGR) | 49.4% | -1.38% |
| Revenue Growth (5Y CAGR) | 147.4% | 4.80% |
Balance sheet
| Measure | Regenerative Medical Technology | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.32M | $22.34M |
| Total Debt | $2.00M | $64.14M |
| Net Cash (Debt) | -$676.70K | $24.44K |
| Net Cash Per Share | -$0.05 | $0.00 |
| Equity (Book Value) | -$39.26M | $22.06M |
| Book Value Per Share | -$2.86 | $0.92 |
| Tangible Book Value | -$40.95M | $1.97M |
| Working Capital | -$40.33M | $2.15M |
Financial position
| Measure | Regenerative Medical Technology | Industry median |
|---|---|---|
| Current Ratio | 0.05 | 1.16 |
| Quick Ratio | 0.03 | 0.44 |
| Debt / EBITDA | 4.92 | 2.93 |
| Net Debt / EBITDA | 1.66 | 1.53 |
| Interest Coverage | 0.00 | -0.20 |
Cash flow (trailing twelve months)
| Measure | Regenerative Medical Technology | Industry median |
|---|---|---|
| Operating Cash Flow | $268.56K | $1.90M |
| Capital Expenditures | -$850.89K | -$11.69M |
| Free Cash Flow | -$582.33K | $9.09M |
| FCF Per Share | -$0.04 | $0.30 |
Efficiency
| Measure | Regenerative Medical Technology | Industry median |
|---|---|---|
| Asset Turnover | 1.82 | 1.48 |
| Inventory Turnover | 12.91 | 5.74 |
| Revenue Per Employee | $9.41M | $406.50K |
| Profits Per Employee | -$9.53M | -$4.56K |
| Employee Count | 1 | 445 |
Dividends and yields
| Measure | Regenerative Medical Technology | Industry median |
|---|---|---|
| Earnings Yield | -1844.5% | -2.24% |
| FCF Yield | -112.7% | 3.52% |
Shares
| Measure | Regenerative Medical Technology | Industry median |
|---|---|---|
| Shares Outstanding | 13,739,000 | 41,358,250 |
| Shares Change (YoY) | 3.32% | 1.64% |
| Shares Change (QoQ) | 4.57% | 0.27% |
| Float | 13,739,000 | 36,489,750 |
| Shares Held by Insiders | 0.00% | 8.11% |
Scores
| Measure | Regenerative Medical Technology | Industry median |
|---|---|---|
| Altman Z-Score | -25.65 | 1.41 |
| Piotroski F-Score | 2 | 5 |
Calculated by StockData from Regenerative Medical Technology's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.